Welcome to our dedicated page for Klotho Neurosciences news (Ticker: KLTO), a resource for investors and traders seeking the latest updates and insights on Klotho Neurosciences stock.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics and biotechnology company whose news flow centers on the development of Klotho gene-based cell and gene therapies for neurodegenerative and age-related disorders. Company announcements describe programs built around a protein derived from a patented form of the human “anti-aging” Klotho gene (s-KL), with a focus on conditions such as ALS, Alzheimer’s disease, and Parkinson’s disease, as well as broader longevity-related indications.
News items for KLTO commonly cover pipeline progress, including manufacturing and development updates for gene therapy candidates like KLTO-101 and KLTO-202, and regulatory milestones such as Orphan Drug Designation for KLTO-202 for the treatment of ALS. Releases also highlight strategic partnerships, notably Klotho’s collaboration with AAVnerGene Inc. to use AAVone and ATHENA platforms for AAV-based manufacturing and tissue-targeted delivery of Klotho gene therapies.
Investors following KLTO news will also see corporate and financing developments, including capital raises, preferred stock transactions described in the company’s S-1 registration statement, and Nasdaq listing and compliance updates. Strategic updates outline Klotho’s efforts to expand beyond neurology into technologies that support healthy brain function, organ health, muscle strength, bone health, and other longevity indicators, as well as its evaluation of complementary longevity-related assets.
Coverage further includes conference participation and scientific engagement, such as presentations at biotech and longevity-focused events and the Inaugural Klotho Conference & Scientific Seminar, where advisors and inventors discuss Klotho gene therapy research. For readers interested in KLTO, this news page aggregates these disclosures so they can review pipeline milestones, partnership announcements, regulatory updates, and strategic communications in one place.
Klotho Neurosciences (NASDAQ: KLTO) announced plans to expand beyond its core neurology focus to evaluate the acquisition of complementary anti-aging technologies. The company aims to develop treatments targeting healthy brain function, organ health, and longevity indicators.
Building on its existing programs KLTO-101 and KLTO-202 for neurodegenerative diseases, Klotho is exploring treatments related to the Klotho gene, which is linked to aging and longevity. The company's expanded focus includes targeting conditions such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia, and osteoporosis.
The initiative involves assembling a scientific team to evaluate genes and proteins including alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin, with the goal of developing interventions to delay age-related diseases.
Klotho Neurosciences (NASDAQ: KLTO) announced plans to expand beyond its core neurology focus to pursue technologies targeting muscle strength, bone health, and longevity indicators. The company is evaluating acquisitions of complementary technologies to support its proprietary anti-aging Klotho platform, while continuing the development of KLTO-101 and KLTO-202.
The expansion focuses on addressing the decline of Klotho levels with age, which contributes to various age-related disorders including cardiometabolic disease, neurodegeneration, cancer, sarcopenia, and osteoporosis. The company is assembling a scientific team to evaluate genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin to develop interventions for age-related diseases.
Klotho Neurosciences (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc. to manufacture its gene therapy candidates using AAVnerGene's advanced AAV manufacturing and tissue-targeted delivery technologies.
The collaboration aims to accelerate the development of KLTO's three key candidates: KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and motor neuron diseases, and KLTO-303 for aging-related pathologies. AAVnerGene's proprietary platforms - AAVone system and ATHENA platform - promise to deliver more cost-effective, faster manufacturing with higher efficacy, purity, and lower toxicity through improved tissue targeting.
Klotho Neurosciences (NASDAQ:KLTO), a gene and cell therapy company focused on neurodegenerative and aging-related diseases, has regained full compliance with NASDAQ's listing requirements. The company has met both the minimum $1.00 bid price requirement and the minimum stockholders' equity threshold of $2.5 million.
While KLTO will maintain its NASDAQ listing, the exchange will continue monitoring the company's compliance with stockholders' equity requirements for one year. If KLTO falls below the minimum equity threshold during this period, it could face delisting but would have the opportunity to request a hearing.
Klotho Neurosciences (NASDAQ:KLTO) has received FDA Orphan Drug Designation for KLTO-202, its novel secreted-Klotho promoter gene therapy for treating Amyotrophic Lateral Sclerosis (ALS). This designation provides significant benefits including tax credits for clinical trials, GDUFA User Fee waivers, and 7 years of market exclusivity.
KLTO-202 targets motor neuron diseases using a muscle-specific promoter called "desmin" to express the s-KL gene and protein, specifically delivering therapy to the neuromuscular junction. The company has completed proof of concept studies in two animal models and is initiating manufacturing while planning regulatory meetings with the FDA and EMA.
Klotho Neurosciences (NASDAQ: KLTO) announced advancement in manufacturing and process development for KLTO-202, its investigational gene therapy treatment for amyotrophic lateral sclerosis (ALS). The company has licensed a unique RNA splice variant of the human alpha-Klotho gene from the Autonomous University of Barcelona for developing advanced gene therapies.
The company's research has demonstrated that overexpression of secreted alpha-Klotho (s-KL) using gene therapy has shown positive therapeutic outcomes in multiple animal studies, including mouse and non-human primate models. The timeline for development indicates approximately 8 months for manufacturing and 4-6 months for regulatory processes, with Phase I/II clinical trials expected to begin by Q3 2026.
KLTO plans to collaborate with contract research organizations (CROs) to manage manufacturing and clinical trials, maintaining operational efficiency without significant staff expansion. The company aims to use an AAV vector to deliver the s-KL gene directly to motor neurons affected by ALS, a disease that typically leads to paralysis and death within 2-3 years of diagnosis.
Klotho Neurosciences (NASDAQ: KLTO) has announced a partnership with the Okinawa Research Center for Longevity Science (ORCLS) to study tissue levels of the human Klotho gene and protein in Okinawa's centenarian population. The research focuses on understanding how the alpha-Klotho protein may contribute to healthy longevity and lifespan.
The collaboration will analyze blood samples from ORCLS's extensive centenarian study database to investigate the role of Klotho protein in promoting longevity and reducing risks of neurodegenerative diseases. KLTO's preliminary data suggests that maintaining optimum blood levels of Klotho protein in later life correlates with longevity, while lower levels are associated with premature aging and neurological disorders.
The company's patent-protected secreted s-KL protein isoform shows promise for treating conditions like ALS, Alzheimer's, Parkinson's, and other age-related disorders including sarcopenia, osteoporosis, diabetes, and cardiovascular conditions.